Compound name
JNJ-42226314
Protein family
Hydrolase
Target name
MGLL
Affinity biochemical (nM)
5
Affinity on-target cellular (nM)
1.13
CG-Set
Other targets set
Recommended Concentration
10 µM
Compound EUbOPEN ID
EUB0002258a
SMILES
O=C(c1ccc2c(ccn2-c2ccc(F)cc2)c1)N1CC(N2CCN(C(=O)c3nccs3)CC2)C1
InChIKey
IVOACCSOISMVBL-UHFFFAOYSA-N
Mode of action
Inhibitor
Negative control
JNJ-8034
Affinity biochemical definition
IC50
Affinity biochemical assay type
Fluorometric assay (inhibition of 4MU-butyrate cleavage)
Affinity Biochemical Source Knowledge
https://pubmed.ncbi.nlm.nih.gov/31818916/
Affinity biochemical relation
<
Affinity on-target cellular definition
IC50
Affinity on-target cellular assay type
Radiometric assay (inhibition of cleavage of [3H] 2-OG using HeLa cells)
Affinity on-target cellular source knowledge
https://pubmed.ncbi.nlm.nih.gov/31818916/
Affinity on-target cellular relation
=
Selectivity platform
Serin Protease panel
Selectivity remarks
Screened at 10 µM against target family members as % of inhibition: Tryptase (2%), Elastase (4%), Plasmin (4%), Chymotrypsin (-3%), TPA (%), Kallikrein (4%), Thrombin (-1%), Chymase (11%), Cathepsin G (13%), Proteinase 3 (7%), Factor VIIa (-5%), Urokinase (2%), Streptokinase (1%9, Trypsin (-10%9, Factor Xa (0%);
In-vitro potency (Radiometric assay using cell lysate and radiolabeled substrate and human FAAH): IC50(FAAH) = 4 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-vitro potency (Radiometric assay using cell lysate and radiolabeled substrate and human ABHD6): IC50(ABHD6) > 10 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-vitro potency (Radiometric assay using cell lysate and radiolabeled substrate and human ABHD12): IC50(ABHD12) >10 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-cellular potency (Fluorescence assay using BODIPY FL containing PLA1-specific substrate, endothelial lipase): IC50 >30 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-cellular potency (Fluorescence assay using BODIPY FL containing PLA1-specific substrate, hepatic lipase): IC50 >30 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-cellular potency (Fluorescence assay using BODIPY FL containing PLA1-specific substrate, lipoprotein lipase): IC50 >30 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
Screened at 10 µM, against 50 kinases, all targets <20% of inhibition, clean screen, data not available, https://pubmed.ncbi.nlm.nih.gov/31818916/;
Screened at 10 µM, against 50 enzymes (CEREP panel), closest targets as % of inhibition: KappaOpioid (66%), 5HT1B (56%), DA transporter (54%), Cl-channel (%), https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-vitro potency (Radiometric assay using cell lysate and radiolabeled substrate and human FAAH): IC50(FAAH) = 4 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-vitro potency (Radiometric assay using cell lysate and radiolabeled substrate and human ABHD6): IC50(ABHD6) > 10 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-vitro potency (Radiometric assay using cell lysate and radiolabeled substrate and human ABHD12): IC50(ABHD12) >10 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-cellular potency (Fluorescence assay using BODIPY FL containing PLA1-specific substrate, endothelial lipase): IC50 >30 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-cellular potency (Fluorescence assay using BODIPY FL containing PLA1-specific substrate, hepatic lipase): IC50 >30 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
In-cellular potency (Fluorescence assay using BODIPY FL containing PLA1-specific substrate, lipoprotein lipase): IC50 >30 µM, https://pubmed.ncbi.nlm.nih.gov/31818916/;
Screened at 10 µM, against 50 kinases, all targets <20% of inhibition, clean screen, data not available, https://pubmed.ncbi.nlm.nih.gov/31818916/;
Screened at 10 µM, against 50 enzymes (CEREP panel), closest targets as % of inhibition: KappaOpioid (66%), 5HT1B (56%), DA transporter (54%), Cl-channel (%), https://pubmed.ncbi.nlm.nih.gov/31818916/;
Selectivity Source Knowledge
https://pubmed.ncbi.nlm.nih.gov/31818916/;